Allergan Sales, LLC v. Sandoz, Inc.
2:15-cv-00347
Overview
Parties
Mediator
David Folsom NPE (Individual / Inventor)
Represented By
1 Attorneys ListedJackson Walker LLP
6002-B Summerfield Drive, Texarkana, TX 75503
Defendant
Sandoz, Inc. Operating Company
Represented By
3 Attorneys ListedThe Davis Firm, PC - Longview
213 North Fredonia Street, Suite 230
Morrison & Foerster LLP San Francisco
425 Market St, 32nd Floor
Morrison & Foerster - San Diego
Morrison & Foerster - San Diego, 12531 High Bluff Dr
Plaintiff
Allergan Sales, LLC Operating Company
Represented By
7 Attorneys ListedSteckler Wayne Cherry & Love, PLLC
PO Box 948, 107 East Main Street
Fish & Richardson P.C. - Wilmington
222 Delaware Avenue, 17th Floor, P O Box 1114
Fish & Richardson - San Diego
Fish & Richardson - San Diego, 12390 El Camino Real
Fish & Richardson PC-Houston
1221 McKinney Street, Ste 2800
Fish & Richardson - San Diego
Fish & Richardson - San Diego, 12390 El Camino Real
Fish & Richardson - Minneapolis
Fish & Richardson - Minneapolis, 60 South Sixth Street
Fish & Richardson PC - San Diego
12860 El Camino Real, Suite 400
Counter Defendant
Court & Judges
Court
District Court, E.D. Texas (txed)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 25 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,030,149 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,323,463 B2 | US Continuation / Sibling | View Official Patent → |
| π PCT International (WIPO) | WO 2003088973 A1 | PCT World Application | View Official Patent → |
| π¨π¦ Canada | CA 002440764 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2440764 C | Canada Counterpart | View Official Patent → |
| π¨π³ China | CN 100558364 C | China Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 3,726,234 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,496,912 B9 | European Counterpart (EP) | View Official Patent → |
| π―π΅ Japan | JP 2003585725 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2005523316 A | Japan Counterpart | View Official Patent → |
| π°π· South Korea | KR 1020037015 | South Korea Counterpart | View Official Patent → |
| π°π· South Korea | KR 100723189 B1 | South Korea Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,010,017,106 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,241,319 A1 | European Counterpart (EP) | View Official Patent → |
| π¨π³ China | CN 2009101744 | China Counterpart | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7030149
Combination of brimonidine timolol for topical ophthalmic use
|
Filed: 2002-04-19
Issued: 2006-04-18
|
Expired (Term Ended)
Expires: 2022-04-19
|
|
|
US7320976
Combination of brimonidine and timolol for topical ophthalmic use
|
Filed: 2003-10-14
Issued: 2008-01-22
|
Expired (Term Ended)
Expires: 2022-12-20
|
|
|
US7642258
Combination of brimonidine and timolol for topical ophthalmic use
|
Filed: 2007-08-24
Issued: 2010-01-05
|
Expired (Term Ended)
Expires: 2022-12-02
|
|
|
US8748425
Combination of brimonidine and timolol for topical ophthalmic use
|
Filed: 2013-08-01
Issued: 2014-06-10
|
Active (6.7 yrs remaining)
Expires: 2033-08-01
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
2
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings